Table 1 Clinical and virological characteristics of studied subjects.
HCV-RNA-positive, anti-HCV-negative blood donors | Chronically HCV-infected patients | |||||||
|---|---|---|---|---|---|---|---|---|
HCV Genotype 1 (n = 35) | HCV Genotype 3 (n = 25) | P | All patients (n = 60) | HCV Genotype 1 (n = 22) | HCV Genotype 3 (n = 19) | P | All patients (n = 41) | |
Subtype | 1b n = 35 | 3a n = 24 Undetermined subtype n = 1 | N/A | 1b n = 22 | 3a n = 18 Undetermined subtype n = 1 | N/A | ||
Sex [M/F] | 33/2 | 20/5 | NS | 53/7 | 10/12 | 11/8 | NS | 21/20 |
Age (years, mean [median], range) | 28.3 [25.0]; 18–55 | 26.2 [23.0]; 19–49 | NS | 27.4 [25]; 18–55 | 45.1 [50.0]; 19–68 | 38.5 [39.0]; 24–58 | NS | 42.1 [40]; 19–68 |
Alanine aminotransferase levels [U L−1]; mean [median], range) ref. values: 10–40 U L−1 | 50.0 [47.0]; 9–143 | 39.8 [37]; 6–74 | NS | 46.1 [44] | 94.1 [73.5] 25–246 | 157.6 [133]; 36–400 | 0.03 | 120.8 [80]; 25–400 |
Viral load [IU mL−1]b; mean [median], range) | 4 700 257 [793 000]; 184–47 800 000 | 5 253 725 [603500]; 2650–69 000 000 | NS | 4 907 808 [775 500]; 184–69 000 000 | 1 219 045 [846 000.0]; 102 000–3 980 000 | 2 642 312 [1 305 000]; 246 000–19 900 000 | NS | 1 818 315 [1 007 500]; 102 000–19 900 000 |
